PANCREAS 2025
Chair: David Goldstein
Comprehensive Profiling of B7 Checkpoint Inhibitors and Associated Immune Response in Pancreatic Neuroendocrine Neoplasms (PanNENs) (126034)
2:00 PM
Targeting the NPY/NPY1R Signaling Axis Impairs Metastasis in Pancreatic Cancer (128230)
2:10 PM
Stopping Pancreatic Cancer in Its Tracks: Anti-Metastatic and Immunomodulatory Effects of a Selective Urokinase Inhibitor (126911)
2:30 PM
Selective Urokinase Inhibition plus Chemotherapy: A Novel Approach to Pancreatic Cancer Treatment via Enhanced Anti-Tumour Immunity and Decreased Metastasis (125930)
2:50 PM
Pulsed Priming with Narmafotinib Reduces Fibrosis and Enhances Both Gemcitabine/Abraxane & FOLFIRINOX Response in Pancreatic Cancer (125885)
3:00 PM
Silencing the Signal: NDRG1 Disrupts Exosome-Mediated Crosstalk in Pancreatic Cancer (125887)
3:10 PM
Overcoming Hepatic Metastasis-Induced Suppression of Adoptive Cell Transfer Immunotherapy for Pancreatic Cancer (125956)
3:20 PM